

Tomas Jelinek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5013629/publications.pdf>

Version: 2024-02-01

44
papers

950
citations

567281

15
h-index

477307

29
g-index

44
all docs

44
docs citations

44
times ranked

1922
citing authors

#	ARTICLE	IF	CITATIONS
1	The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3176-3187.	7.0	156
2	<sc>PD</sc>-1/<sc>PD</sc>-L1 inhibitors in haematological malignancies: update 2017. <i>Immunology</i> , 2017, 152, 357-371.	4.4	108
3	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2431.	4.8	85
4	Venetoclax: A new wave in hematocology. <i>Experimental Hematology</i> , 2018, 61, 10-25.	0.4	73
5	Extramedullary disease in multiple myeloma – controversies and future directions. <i>Blood Reviews</i> , 2019, 36, 32-39.	5.7	66
6	Monoclonal antibodies – A new era in the treatment of multiple myeloma. <i>Blood Reviews</i> , 2016, 30, 101-110.	5.7	43
7	Plasma cell leukemia: from biology to treatment. <i>European Journal of Haematology</i> , 2015, 95, 16-26.	2.2	37
8	Cytogenetics in multiple myeloma patients progressing into extramedullary disease. <i>European Journal of Haematology</i> , 2016, 97, 93-100.	2.2	37
9	Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). <i>American Journal of Hematology</i> , 2019, 94, E35-E37.	4.1	35
10	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.8	31
11	Intercellular Mitochondrial Transfer in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 1787.	3.7	25
12	Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 104, 190-197.	2.2	23
13	Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. <i>Leukemia</i> , 2022, 36, 288-291.	7.2	23
14	Monoclonal antibodies in the treatment of AL amyloidosis: co-targeting the plasma cell clone and amyloid deposits. <i>British Journal of Haematology</i> , 2020, 189, 228-238.	2.5	19
15	FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology. <i>Blood Advances</i> , 2022, 6, 690-703.	5.2	19
16	Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. <i>British Journal of Haematology</i> , 2021, 193, 705-722.	2.5	18
17	Natural Killer Cells in the Malignant Niche of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 816499.	4.8	14
18	Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. <i>Current Medical Research and Opinion</i> , 2018, 34, 775-783.	1.9	11

#	ARTICLE	IF	CITATIONS
19	Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort. <i>Hematological Oncology</i> , 2020, 38, 412-414.	1.7	11
20	Cytarabine+G-CSF is more effective than cyclophosphamide+G-CSF as a stem cell mobilization regimen in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1107-1114.	2.4	10
21	Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2019, 163, 279-283.	0.6	10
22	A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. <i>Cancers</i> , 2020, 12, 1333.	3.7	9
23	Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. <i>Cells</i> , 2021, 10, 967.	4.1	9
24	Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies. <i>Frontiers in Pharmacology</i> , 2021, 12, 733890.	3.5	9
25	Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers. <i>Blood Reviews</i> , 2021, 46, 100758.	5.7	8
26	Identification of patients at high risk of secondary extramedullary multiple myeloma development. <i>British Journal of Haematology</i> , 2021, , .	2.5	8
27	Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints. <i>Blood</i> , 2021, 138, 76-76.	1.4	7
28	Venetoclax: the first anti-myeloma agent with a reliable biomarker. <i>British Journal of Haematology</i> , 2020, 189, 1003-1005.	2.5	6
29	Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia. <i>British Journal of Haematology</i> , 2021, 195, 95-107.	2.5	6
30	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11470.	4.1	6
31	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. <i>Expert Review of Hematology</i> , 2020, 13, 375-392.	2.2	5
32	Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 1959-1959.	1.4	4
33	Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. <i>Blood Advances</i> , 2021, , .	5.2	3
34	Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse. <i>Blood</i> , 2016, 128, 5653-5653.	1.4	3
35	CD38-Targeted treatment for multiple myeloma. <i>Vnitri Lekarstvi</i> , 2018, 64, 939-948.	0.2	3
36	Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2019, 134, 3139-3139.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. American Journal of Hematology, 2022, , .	4.1	2
38	Management of Treatment-Related Infectious Complications in High-Risk Hemato-Oncological Patients via Telemedicine. Cancer Management and Research, 2022, Volume 14, 1655-1661.	1.9	2
39	Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European Journal of Haematology, 2021, 107, 466-474.	2.2	1
40	Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients. Blood, 2016, 128, 3332-3332.	1.4	1
41	Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice. Blood, 2021, 138, 2716-2716.	1.4	1
42	Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2021, 138, 2764-2764.	1.4	1
43	Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling. Blood, 2020, 136, 16-17.	1.4	0
44	Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients. Blood, 2020, 136, 40-42.	1.4	0